Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)
This trial is active, not recruiting.
|Treatment||rheopheresis blood filtration|
|Start date||August 1999|
|End date||December 2005|
|Trial size||180 participants|
|Trial identifier||NCT00078221, AMD-02-99|
AMD is a progressive disease of the retina which is nourished by a network of tiny blood vessels. There is evidence to suggest that the flow of nutrients to the retina is impaired in patients with AMD. Rheopheresis blood filtration uses blood filters that deplete excesses of large proteins, fats and other substances from the blood, improving blood flow to the macula, potentially improving vision.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Beverly Hills, CA||Retina Vitreous Associates||no longer recruiting|
|Coral Gables, FL||Aran Eye Associates||no longer recruiting|
|Ft. Myers, FL||Retina Health Care||no longer recruiting|
|Chicago, IL||UIC Eye Center||no longer recruiting|
|New York, NY||Macula Care||no longer recruiting|
|Southern Pines, NC||Carolina Eye Associates||no longer recruiting|
|Bala Cynwyd, PA||Associated Retinal Consultants||no longer recruiting|
|Oakville,, Canada||W. Bradley Kates, MD||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Male or female participants from 50 years up to 85 years old.
- Age 50-85 - Diagnosis of Dry AMD - BCVA between 20/32 and 20/125 in at least one eye - Numerous large plaques (soft drusen) - No history of HIV, Hepatitis B or C - Elevation of certain blood factors, such as total cholesterol, fibrinogen, and IgA
Call for more information